Author

Andrew Bassim Hassan

Observed names: A. Bassim Hassan, Hassan, Andrew Bassim

Institution: University of Oxford

Observed institutions: University of Oxford, Oxford University Hospitals NHS Trust

ORCID: 0000-0002-2517-6681

Observed ORCID: 0000-0002-2517-6681

OpenAlex ID: A5012929336

A phase I/II dose escalation and expansion study of cabiralizumab (cabira; FPA-008), an anti-CSF1R antibody, in tenosynovial giant cell tumor (TGCT, diffuse pigmented villonodular synovitis D-PVNS).

2017 · Kamalesh Kumar Sankhala, Jean-Yves Blay, et al. · Journal of Clinical Oncology · 44

Challenges and solutions to system-wide use of precision oncology as the standard of care paradigm

2024 · Nesrine Lajmi, Sofia Alves-Vasconcelos, et al. · Cambridge Prisms Precision Medicine · 25

An open-label international multicentric phase II study of nilotinib in progressive pigmented villo-nodular synovitis (PVNS) not amenable to a conservative surgical treatment.

2013 · Hans Gelderblom, David Pérol, et al. · Journal of Clinical Oncology · 19

Outcomes from a mechanistic biomarker multi-arm and randomised study of liposomal MTP-PE (Mifamurtide) in metastatic and/or recurrent osteosarcoma (EuroSarc-Memos trial)

2022 · David J. Barnes, Peter Dutton, et al. · BMC Cancer · 16

An open-label international multicentric phase II study of nilotinib in progressive pigmented villo-nodular synovitis (PVNS) not amenable to a conservative surgical treatment.

2012 · Isabelle Ray-Coquard, Hans Gelderblom, et al. · Journal of Clinical Oncology · 12

Tumour neoantigen repertoire computational predictions in malignant peripheral nerve sheath tumours define potential targets for immunotherapy

2026 · Mirvat Surakhy, Joseph E. Caesar, et al. · bioRxiv (Cold Spring Harbor Laboratory)

Works count: 9

Citation count: 116

H-index: 5

I10-index: 5